|Day Low/High||101.44 / 107.14|
|52 Wk Low/High||51.73 / 179.65|
Exelixis and Ultragenyx Pharmaceutical are cash rich mid-caps that don't look overbought.
When I first started buying ARCT shares I didn't conceive of a valuation of $1 billion, but I also didn't conceive of the global impact of a pandemic.
Indices have not changed much since my last post and the market remains solidly in the green. Not a big rise, but a steady one. Strength in the market continues to be mostly in the small cap names as it has for most of the last week. The Russell 200...
When the indices aren't offering much opportunity money flows into individual speculative names.
A look at three names to consider in the biotech and biopharma space.
The Cambridge, Mass.-based Ironwood unveiled top-line data from a pair of Phase 2a studies evaluating IW-1973 in patients that have type 2 diabetes and hypertension.
Only one fund category (of 20) has beaten the S&P 500 over half a decade.